IDEAYA Biosciences, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
IDEAYA Biosciences, Inc. (IDYA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $320.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-04
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $158.37M, a 9.05% decline year-over-year.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $162.53M, a 12.78% decline year-over-year.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $138.94M, a 1.48% decline year-over-year.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $180.80M, a 6.87% decline year-over-year.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $680.23M, a 1.79% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $692.61M, a 57.45% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $439.89M, a 94.77% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $225.85M, a 7.42% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $158.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $320.90M 10-Q · filed 2026-08-04 | $459.84M derived: sum of 3 quarters · filed 2026-08-04 | $640.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $162.53M 10-Q · filed 2026-05-05 | $301.47M derived: sum of 2 quarters · filed 2026-05-05 | $482.27M derived: sum of 3 quarters · filed 2026-05-05 | $656.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $138.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $319.75M derived: sum of 2 quarters · filed 2026-02-17 | $493.88M derived: sum of 3 quarters · filed 2026-08-04 | $680.23M 10-K · filed 2026-02-17 |
| 2025-09-30 | $180.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $354.93M derived: sum of 2 quarters · filed 2026-08-04 | $541.29M 10-Q · filed 2025-11-04 | $682.32M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $174.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $360.49M 10-Q · filed 2026-08-04 | $501.52M derived: sum of 3 quarters · filed 2026-08-04 | $695.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $186.35M 10-Q · filed 2026-05-05 | $327.39M derived: sum of 2 quarters · filed 2026-05-05 | $521.53M derived: sum of 3 quarters · filed 2026-05-05 | $755.83M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $141.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $335.18M derived: sum of 2 quarters · filed 2026-02-17 | $569.47M derived: sum of 3 quarters · filed 2026-02-17 | $692.61M 10-K · filed 2026-02-17 |
| 2024-09-30 | $194.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $428.44M derived: sum of 2 quarters · filed 2025-11-04 | $551.57M 10-Q · filed 2025-11-04 | $662.07M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $234.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $357.43M 10-Q · filed 2025-08-05 | $467.93M derived: sum of 3 quarters · filed 2026-02-17 | $601.71M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $123.14M 10-Q · filed 2025-05-06 | $233.63M derived: sum of 2 quarters · filed 2026-02-17 | $367.42M derived: sum of 3 quarters · filed 2026-02-17 | $467.17M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $110.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $244.28M derived: sum of 2 quarters · filed 2026-02-17 | $344.03M derived: sum of 3 quarters · filed 2026-02-17 | $439.89M 10-K · filed 2026-02-17 |
| 2023-09-30 | $133.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $233.53M derived: sum of 2 quarters · filed 2024-11-04 | $329.39M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $99.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $195.61M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $95.86M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $225.85M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $243.96M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |